Contact
searchSearch
HMP Global
Login

Chronic Myeloid Leukemia Resource Center

News
Increasing TKI Utilization and Costs for CML Put Pressure on Medicare Part-D Insurers
09/20/2021
The increase in use of TKIs for patients with CML and the increase in TKI drug prices place considerable financial pressure on Medicare part-D insurers.
The increase in use of TKIs for patients with CML and the increase in TKI drug prices place considerable financial pressure on Medicare part-D insurers.
The increase in use of TKIs for...
09/20/2021
Journal of Clinical Pathways
Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
ENGAGING EXPERTS
Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
01/14/2021
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses...
01/14/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Treatment Patterns, Health Care Resource Utilization, and Costs in CML
12/05/2020
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and results in high medical costs.
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and results in high medical costs.
For patients with CML, switching...
12/05/2020
Journal of Clinical Pathways
Economic Burden of CML Treatment in the US: Before and After the Availability of Generic Imatinib
ENGAGING EXPERTS
Economic Burden of CML Treatment in the US: Before and After the Availability of Generic Imatinib
10/03/2020
Gary Lyman, MD, discusses a project exploring the cost of TKIs, particularly imatinib and generic imatinib, for the treatment of patients with CML.
Gary Lyman, MD, discusses a project exploring the cost of TKIs, particularly imatinib and generic imatinib, for the treatment of patients with CML.
Gary Lyman, MD, discusses a...
10/03/2020
Journal of Clinical Pathways
Trend in TKI Use, Adherence, and Switching Patterns in Patients With CML: Before and After the Availability of Generic Imatinib
Research Reports
Trend in TKI Use, Adherence, and Switching Patterns in Patients With CML: Before and After the Availability of Generic Imatinib
08/19/2020
Abstract: The therapeutic landscape for chronic myeloid leukemia (CML) has evolved substantially over the past decade, most notably with the introduction of second- and third-generation tyrosine kinase inhibitors...
Abstract: The therapeutic landscape for chronic myeloid leukemia (CML) has evolved substantially over the past decade, most notably with the introduction of second- and third-generation tyrosine kinase inhibitors...
...
08/19/2020
Journal of Clinical Pathways
Research in Review
Dose Escalation of CML Treatment Improves Molecular Response Rates
08/02/2017
JCP Editors
Patients with chronic myeloid leukemia (CML) in the chronic phase may achieve molecular response with safe and effective treatment dose escalation, according to a recent study. ----- Related Content CML Mutations...
Patients with chronic myeloid leukemia (CML) in the chronic phase may achieve molecular response with safe and effective treatment dose escalation, according to a recent study. ----- Related Content CML Mutations...
...
08/02/2017
Journal of Clinical Pathways
Research in Review
CML Treatment Decisions Should Factor in Cardiovascular Disease Risk
07/27/2017
JCP Editors
Cardiovascular disease rates and its associated risks are increased in patients with chronic myelogenous leukemia (CML) treated by community-based oncologists and should impact treatment decisions, according to a...
Cardiovascular disease rates and its associated risks are increased in patients with chronic myelogenous leukemia (CML) treated by community-based oncologists and should impact treatment decisions, according to a...
...
07/27/2017
Journal of Clinical Pathways
Research in Review
Second TKI Discontinuation Attempt Safe in Patients With CML
07/27/2017
JCP Editors
Patients with chronic myeloid leukemia (CML) who attempt to discontinue tyrosine kinase inhibitor (TKI) therapy for a second time after a first unsuccessful attempt have strong treatment-free remission rates,...
Patients with chronic myeloid leukemia (CML) who attempt to discontinue tyrosine kinase inhibitor (TKI) therapy for a second time after a first unsuccessful attempt have strong treatment-free remission rates,...
...
07/27/2017
Journal of Clinical Pathways

Expert Insights

Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
ENGAGING EXPERTS
Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
01/14/2021
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses...
01/14/2021
Journal of Clinical Pathways
Economic Burden of CML Treatment in the US: Before and After the Availability of Generic Imatinib
ENGAGING EXPERTS
Economic Burden of CML Treatment in the US: Before and After the Availability of Generic Imatinib
10/03/2020
Gary Lyman, MD, discusses a project exploring the cost of TKIs, particularly imatinib and generic imatinib, for the treatment of patients with CML.
Gary Lyman, MD, discusses a project exploring the cost of TKIs, particularly imatinib and generic imatinib, for the treatment of patients with CML.
Gary Lyman, MD, discusses a...
10/03/2020
Journal of Clinical Pathways
Davids Headshot
Interview
Integrating Real-World Evidence and Clinical Trial Data in CLL Management
01/17/2025
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S....
01/17/2025
Journal of Clinical Pathways
Romano Headshot
Interview
Personalizing Radiotherapy for Endometrial Cancer: Balancing Innovation and Quality of Life
01/17/2025
In this interview, Kara D. Romano, MD, University of Virginia, discusses advancements in radiation therapy for endometrial cancer, the integration of systemic therapies, the impact of treatment on quality of life, and the role of clinical...
In this interview, Kara D. Romano, MD, University of Virginia, discusses advancements in radiation therapy for endometrial cancer, the integration of systemic therapies, the impact of treatment on quality of life, and the role of clinical...
In this interview, Kara D....
01/17/2025
Journal of Clinical Pathways
Ma Headshot
Interview
Advancing Biomarker Validation and Emerging Treatments in Metastatic Breast Cancer
01/16/2025
In this interview, Cynthia X. Ma, MD, PhD, Washington University School of Medicine, discusses challenges in biomarker validation, the role of combination therapies, promising novel agents, and the integration of emerging treatments for...
In this interview, Cynthia X. Ma, MD, PhD, Washington University School of Medicine, discusses challenges in biomarker validation, the role of combination therapies, promising novel agents, and the integration of emerging treatments for...
In this interview, Cynthia X....
01/16/2025
Journal of Clinical Pathways
Bhat Headshot
Interview
Novel Therapies and Their Impact on Treatment Pathways for Chronic Lymphocytic Leukemia
01/13/2025
In this interview, Seema A. Bhat, MD, discusses the evolving treatment landscape for chronic lymphocytic leukemia, including strategies for treatment selection, sequencing, addressing diagnostic gaps, and exploring novel therapies to improve...
In this interview, Seema A. Bhat, MD, discusses the evolving treatment landscape for chronic lymphocytic leukemia, including strategies for treatment selection, sequencing, addressing diagnostic gaps, and exploring novel therapies to improve...
In this interview, Seema A....
01/13/2025
Journal of Clinical Pathways
Meisel Headshot
Interview
Improving Early Detection and Treatment for Breast Cancer Patients
01/10/2025
In this interview, Jane L. Meisel, MD, discusses advancements in early breast cancer detection, the integration of standard and emerging treatments, strategies for improving patient adherence, and opportunities for optimizing care through...
In this interview, Jane L. Meisel, MD, discusses advancements in early breast cancer detection, the integration of standard and emerging treatments, strategies for improving patient adherence, and opportunities for optimizing care through...
In this interview, Jane L....
01/10/2025
Journal of Clinical Pathways
BDHC Thumbnail
Videos
Alternative Payment Models in Health Care: Successes, Failures, and What’s Next
01/09/2025
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the evolution and challenges of alternative payment models, including accountable care organizations (ACOs), the Oncology Care Model (OCM),...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the evolution and challenges of alternative payment models, including accountable care organizations (ACOs), the Oncology Care Model (OCM),...
In this Breaking Down Health...
01/09/2025
Cancer Care Business Exchange
Patel Headshot
Interview
Evolving Clinical Pathways for Perioperative Strategies in Resectable NSCLC
01/09/2025
In this interview, Sandip Patel, MD, discusses the evolution of clinical pathways for non-small cell lung cancer (NSCLC), including the integration of perioperative strategies, the potential of immunotherapy in earlier stages, the role of...
In this interview, Sandip Patel, MD, discusses the evolution of clinical pathways for non-small cell lung cancer (NSCLC), including the integration of perioperative strategies, the potential of immunotherapy in earlier stages, the role of...
In this interview, Sandip Patel,...
01/09/2025
Journal of Clinical Pathways
Interview
Transforming Treatment Pathways for Endometrial Cancer
12/20/2024
In this interview, Floortje Backes, MD, The Ohio State University College of Medicine, discusses advancements in novel treatments, the impact of molecular classifications, evolving surgical approaches, barriers to standardizing care, and...
In this interview, Floortje Backes, MD, The Ohio State University College of Medicine, discusses advancements in novel treatments, the impact of molecular classifications, evolving surgical approaches, barriers to standardizing care, and...
In this interview, Floortje...
12/20/2024
Journal of Clinical Pathways
Lisa Herms
Conference Coverage
Impact of Bispecific Antibodies on Treatment Patterns and Patient Characteristics in Multiple Myeloma
12/19/2024
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world...
12/19/2024
Journal of Clinical Pathways
Shaverdian Headshot
Interview
Incorporating Precision Medicine and AI Into NSCLC Radiation Approaches
12/19/2024
In this interview, Narek Shaverdian, MD, discusses the evolving role of radiation therapy in NSCLC treatment, highlighting advancements in precision medicine, the integration of AI, and promising research aimed at improving patient outcomes.
In this interview, Narek Shaverdian, MD, discusses the evolving role of radiation therapy in NSCLC treatment, highlighting advancements in precision medicine, the integration of AI, and promising research aimed at improving patient outcomes.
In this interview, Narek...
12/19/2024
Journal of Clinical Pathways

Newsfeed

News
Increasing TKI Utilization and Costs for CML Put Pressure on Medicare Part-D Insurers
09/20/2021
The increase in use of TKIs for patients with CML and the increase in TKI drug prices place considerable financial pressure on Medicare part-D insurers.
The increase in use of TKIs for patients with CML and the increase in TKI drug prices place considerable financial pressure on Medicare part-D insurers.
The increase in use of TKIs for...
09/20/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Treatment Patterns, Health Care Resource Utilization, and Costs in CML
12/05/2020
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and results in high medical costs.
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and results in high medical costs.
For patients with CML, switching...
12/05/2020
Journal of Clinical Pathways
News
Racial Disparities in Immune Checkpoint Inhibitor Treatment and Survival Among Patients With NSCLC
01/15/2025
Disparities in immune checkpoint inhibitor utilization and survival based on race and socioeconomic factors in patients with metastatic non-small cell lung cancer (NSCLC) underscore the need for improved access to care for vulnerable...
Disparities in immune checkpoint inhibitor utilization and survival based on race and socioeconomic factors in patients with metastatic non-small cell lung cancer (NSCLC) underscore the need for improved access to care for vulnerable...
Disparities in immune checkpoint...
01/15/2025
Journal of Clinical Pathways
News
Social Risks Lower Rates of Preventive Cancer Screenings
01/09/2025
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI...
01/09/2025
Journal of Clinical Pathways
News
A Deep Learning Model for Predicting Immune Checkpoint Inhibitor Efficacy in NSCLC
01/08/2025
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and...
01/08/2025
Journal of Clinical Pathways
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Refining Risk Stratification for Myelofibrosis Using Real-World Data
12/20/2024
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in...
12/20/2024
Journal of Clinical Pathways
Lisa Herms
Conference Coverage
Impact of Bispecific Antibodies on Treatment Patterns and Patient Characteristics in Multiple Myeloma
12/19/2024
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world...
12/19/2024
Journal of Clinical Pathways
News
Travel and Financial Burdens Play a Role in Cancer Care
12/19/2024
The joint stressors of travel burdens and financial hardship can affect the care patients with cancer receive.
The joint stressors of travel burdens and financial hardship can affect the care patients with cancer receive.
The joint stressors of travel...
12/19/2024
Journal of Clinical Pathways
News
An Evaluation of Endometrial Cancer Guidelines for Optimal Patient Care
12/17/2024
A review published in Cancers compares multiple guidelines on managing endometrial cancer, emphasizing the importance of consistent protocols and the role of molecular classification in optimizing treatment for postmenopausal women.
A review published in Cancers compares multiple guidelines on managing endometrial cancer, emphasizing the importance of consistent protocols and the role of molecular classification in optimizing treatment for postmenopausal women.
A review published in Cancers...
12/17/2024
Journal of Clinical Pathways
News
Cancer Predisposition Genes Found in 1 in 10 Patients With Multiple Myeloma
12/17/2024
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients...
12/17/2024
Journal of Clinical Pathways
News
Exploring Lipid Metabolism Pathways in Endometrial Cancer Growth and Metastasis
12/17/2024
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as...
12/17/2024
Journal of Clinical Pathways

Interactive Features

SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
Nov-Dec 2024 Issue Cover

Current Issue

December 2024
Volume 10
Issue 6
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

News
Increasing TKI Utilization and Costs for CML Put Pressure on Medicare Part-D Insurers
09/20/2021
The increase in use of TKIs for patients with CML and the increase in TKI drug prices place considerable financial pressure on Medicare part-D insurers.
The increase in use of TKIs for patients with CML and the increase in TKI drug prices place considerable financial pressure on Medicare part-D insurers.
The increase in use of TKIs for...
09/20/2021
Journal of Clinical Pathways
Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
ENGAGING EXPERTS
Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
01/14/2021
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses...
01/14/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Treatment Patterns, Health Care Resource Utilization, and Costs in CML
12/05/2020
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and results in high medical costs.
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and results in high medical costs.
For patients with CML, switching...
12/05/2020
Journal of Clinical Pathways
Economic Burden of CML Treatment in the US: Before and After the Availability of Generic Imatinib
ENGAGING EXPERTS
Economic Burden of CML Treatment in the US: Before and After the Availability of Generic Imatinib
10/03/2020
Gary Lyman, MD, discusses a project exploring the cost of TKIs, particularly imatinib and generic imatinib, for the treatment of patients with CML.
Gary Lyman, MD, discusses a project exploring the cost of TKIs, particularly imatinib and generic imatinib, for the treatment of patients with CML.
Gary Lyman, MD, discusses a...
10/03/2020
Journal of Clinical Pathways
Trend in TKI Use, Adherence, and Switching Patterns in Patients With CML: Before and After the Availability of Generic Imatinib
Research Reports
Trend in TKI Use, Adherence, and Switching Patterns in Patients With CML: Before and After the Availability of Generic Imatinib
08/19/2020
Abstract: The therapeutic landscape for chronic myeloid leukemia (CML) has evolved substantially over the past decade, most notably with the introduction of second- and third-generation tyrosine kinase inhibitors...
Abstract: The therapeutic landscape for chronic myeloid leukemia (CML) has evolved substantially over the past decade, most notably with the introduction of second- and third-generation tyrosine kinase inhibitors...
...
08/19/2020
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use